Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-8-20
pubmed:abstractText
Over the past several years many advances have been made in our understanding of critical pathways involved in carcinogenesis and tumor growth. These advances have led to the investigation of small molecule inhibitors of the ErbB family of receptor tyrosine kinases across a broad spectrum of malignancies. In this article we summarize the rationale for targeting members of the ErbB family in breast cancer, and review the preclinical and clinical data for the agents that are furthest in development. In addition, we highlight directions for future research, such as exploration of the potential crosstalk between the ErbB and hormone receptor signal transduction pathways, identification of predictive markers for tumor sensitivity, and development of rational combination regimens that include the tyrosine kinase inhibitors.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-10561337, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-11248153, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-11390655, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-11859875, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12297041, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12538510, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12845624, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12860956, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12860957, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12885806, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12897327, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-12954573, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-1313356, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-14737100, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-14993230, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-15084248, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-15118073, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-15118125, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-2161707, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-3798106, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-7515147, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-7585629, http://linkedlifedata.com/resource/pubmed/commentcorrection/15318926-8688326
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1465-542X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
204-10
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.
pubmed:affiliation
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
pubmed:publicationType
Journal Article, Review